BioCentury
ARTICLE | Company News

Shionogi, Viiv Healthcare sales and marketing update

April 28, 2014 7:00 AM UTC

ViiV and Shionogi launched ViiV's Tivicay dolutegravir in Japan to treat HIV infection in combination with other HIV drugs in patients ages 12 years and older. Japan's Ministry of Health, Labor and Welfare (MHLW) approved the HIV integrase inhibitor in March. The National Health Insurance (NHI) list price is ¥3,262.50 ($31.97) for a 50 mg tablet. The recommended dose is 50 mg once daily for patients who are treatment-naïve or have not received treatment with integrase inhibitors, and 50 mg twice daily for patients with resistance to integrase inhibitors. ...